Asset profile

Vebreltinib

Small molecule

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-12-31.

How the evidence outlook works ↗

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (3)
September 2026 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-09 · NCT06827145 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-10-31 · NCT06574347 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06343064 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (6)
January 2027 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT04743505 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04 · NCT07087223 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-20 · NCT07153770 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07156604 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-03 · NCT07655622 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06970782 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
May 2028 (1)
Phase 2Lung NeoplasmsNot yet recruiting
Est. primary completion 2028-05-30 · NCT07549061 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)
February 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02 · NCT06930794 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-11-01 · NCT06644313 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.